EXEL:NASDAQExelixis, Inc. Analysis

Exelixis is trading just above its 20‑day simple moving average, which sits comfortably above the 50‑day and 200‑day averages, signaling a sustained uptrend. The MACD line remains bullish and its histogram is positive, while the 14‑day RSI hovers around the low‑60s, indicating momentum without being overbought. Price action is testing the $53.93 resistance level but finds support near $48.10, and the current market price of $53.13 reflects modest upside potential. Fundamentally, the company posted a 10% year‑over‑year revenue increase to $610.8 million, maintains a gross margin above 96% and an operating margin over 41%, delivering strong free cash flow. The forward P/E of 13.1 is well below the biotechnology industry average of 24.8, and the DCF‑derived fair value of $52.97 is only marginally below the market price, suggesting the stock is fairly priced at best. Recent news highlights a Phase 3 collaboration with Merck on a colorectal cancer trial and positive ASCO presentations for its flagship and pipeline assets, providing a catalyst narrative. With a beta under 1 and a 30‑day volatility near 46%, the stock exhibits moderate market sensitivity, while its low debt and ample cash cushion balance risk. Overall, the blend of solid earnings, attractive valuation multiples, and upcoming clinical data supports a cautiously optimistic outlook.